-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Rongchang Biotechnology and Seagen reached a US$2.
6 billion global exclusive license agreement to develop and commercialize its antibody-conjugated drug (ADC) vedicitumumab
.
As soon as the heavy news came out, it once again aroused everyone's attention to new immunotherapies such as ADC
Target differentiation, list of ADC approvals in 2021
Target differentiation, list of ADC approvals in 2021 According to incomplete statistics, a total of 5 drugs received marketing approval or new indications this year.
4 were approved by the US FDA and 1 was approved by the China Food and Drug Administration (NMPA).
They are enfortumab vedotin, loncastuximab tesirine, and sacituzumab govitecan.
, Trastuzumab deruxtecan and vedicitumumab
.
From previous years, HER2, Trop2, Claudi 18.
Strong cooperation, ADC authorization cooperation continues to increase
Strong cooperation, ADC authorization cooperation continues to increase In addition to drug authorization, there are also examples of companies using the drug R&D technologies and platforms of both parties to jointly develop antibody-conjugated drugs
.
ADC's therapeutic areas are concentrated in the field of oncology, but there are also several diseases involving the blood system, respiratory system, and gynecology
*Highlight trading events
*Highlight trading events On June 17, Eisai and Bristol-Myers Squibb (BMS) collaborated to develop MORAb-202, which is a folate receptor α-antibody conjugate (FRα-ADC)
.
The total amount of the transaction is as high as 3.
Main body: Eisai
Partner: Bristol-Myers Squibb (BMS)
Treatment fields: anti-tumor, respiratory system, gynecology
Transaction amount: US$3.
1 billion
Transaction subject: MORAb-202
Target: FRα
The drug consists of the antifolate receptor alpha (FRα) antibody farletuzumab developed by Eisai and the anticancer drug eribulin
.
The press release pointed out that the drug is a potential "best-in-class" FRα ADC with good pharmacological characteristics and shows single-agent activity in patients with advanced solid tumors
Competing on the same stage, the future can be expected
Competing on the same stage, the future can be expected Since January 2021, there have been 10 blockbuster transactions in the field of antibody conjugate drugs worldwide, including 4 drug authorization transactions and 6 transaction cooperation projects
.
According to the data, the United States, China, and Europe are advancing side by side in the ADC field, accounting for 25%, and Korean companies have excellent cooperation, accounting for 15%
In short, combining the similarities and differences of approved drugs, transaction authorizations, and drug targets in R&D cooperation, we can see how different companies enter the ADC on the track of selecting targets
.
Pharmaceutical companies have entered the ADC track one after another, so you can consider the difference of targets and try on different tracks
Reference materials:
Reference materials:[1] Rongchang Biotech signed a contract with Seattle Gene: $2.
[1] Rongchang Biotech signed a contract with Seattle Gene: $2.
[2] Eisai and Bristol Myers Squibb Enter IntoGlobal Strategic Collaboration for Eisai's MORAb-202Antibody Drug Conjugate.
Retrieved June 17, 2021, from https://news.
bms.
com/news/details/2021/Eisai-and-Bristol-Myers -Squibb-Enter-Into-Global-Strategic-Collaboration-for-Eisais-MORAb-202-Antibody-Drug-Conjugate/default.
aspx
